Agios Pharmaceuticals

ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.

Schrödinger has terminated development of its CDC7 inhibitor SGR-2921 after two patient deaths in a Phase I trial for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

The FDA has extended the review period for Agios Pharmaceuticals' Pyrukynd (mitapivat) in thalassemia, pushing the PDUFA date from September 7, 2025 to December 7, 2025 due to a required Risk Evaluation and Mitigation Strategy (REMS) submission.

Avanzanite Bioscience has secured exclusive European commercialization rights for PYRUKYND® (mitapivat), a first-in-class pyruvate kinase activator approved for treating adults with PK deficiency.

DelveInsight's 2025 assessment reveals a robust sickle cell disease pipeline with 55+ companies developing 60+ therapeutic candidates across various clinical development stages.

• Dr. Eyal Attar joins Halda Therapeutics as Chief Medical Officer, bringing over 25 years of biotechnology R&D and clinical trial experience to advance the company's novel RIPTAC cancer therapy platform. • Halda is currently conducting a Phase 1/2 clinical trial of HLD-0915, their lead candidate targeting metastatic castration-resistant prostate cancer (mCRPC) through a unique "hold and kill" mechanism designed to overcome resistance. • The RIPTAC platform represents a new therapeutic modality that creates neomorphic protein-protein interactions to selectively target cancer cells, with programs in development for prostate cancer, breast cancer, and other serious diseases.

Mitapivat demonstrated significant efficacy in the ACTIVATE-Kids Phase 3 trial, becoming the first oral therapy to show positive results in children with non-transfusion-dependent PK deficiency.

Agios Pharmaceuticals is developing Tebapivat (AG-946), an oral PKR activator, targeting multiple hemolytic anemic conditions including sickle cell disease and PK deficiency.

The European Commission has granted orphan medicinal product designation to mitapivat for the treatment of sickle cell disease, offering benefits like reduced fees and market exclusivity.

Updated data from the phase 3 INDIGO study demonstrates vorasidenib's continued efficacy in patients with IDH1/2-mutated diffuse glioma.